Editas Medicine is a clinical stage genome editing company focused on developing genomic medicines to treat a range of serious diseases. Co. has developed a proprietary genome editing platform based on clustered, regularly interspaced, short palindromic repeats technology and it continues to expand its capabilities. Co. is developing in vivo gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body, ex vivo gene-edited cell medicines, in which cells collected from a patient are edited with Co.'s technology and then administered back to that same patient, and cellular therapy medicines.